Bugging inflammation in lung cancer

How the lung microbiome highlights therapeutic avenues for lung cancer

An MIT study linking the lung microbiome to inflammation offers new therapeutic strategies for treating lung cancer and a mechanistic rationale for testing cytokine inhibitors in the disease, a tack Novartis AG (NYSE:NVS; SIX:NOVN) has already taken.

In a Cell paper last month, a team from the

Read the full 465 word article

How to gain access

Continue reading with a
two-week free trial.